Karis Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 36

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $8.24M

  • Investors
  • 8

Karis Bio General Information

Description

Developer of a cell based therapeutic system designed for the treatment of cardiovascular conditions. The company's platform utilizes induced pluripotent stem cell generation and endothelial cell differentiation technologies, supports the development of human derived endothelial cells for neovascularization, incorporates applications spanning peripheral arterial disease, ischemic heart disease, diabetic retinopathy, diabetic neuropathy, and wound healing, and integrates clinical trial activities for multiple cardiovascular indications, enabling the biotechnology and healthcare markets to access regenerative treatment options that support vascular repair and functional recovery.

Contact Information

Website
www.karisbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 50-1 Seongsan-ro
  • Seodaemun-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 50-1 Seongsan-ro
  • Seodaemun-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karis Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 01-Dec-2024 $8.24M Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 07-Aug-2021 Completed Clinical Trials - General
1. Angel (individual) 01-Dec-2020 Completed Clinical Trials - General
To view Karis Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Karis Bio Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Karis Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12447181-B2 Method of isolation of culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same Active 13-Nov-2019
AU-2020382287-A1 Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same Inactive 13-Nov-2019
AU-2025200333-A1 Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same Pending 13-Nov-2019
CA-3156948-A1 Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same Pending 13-Nov-2019
EP-4060024-A1 Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same Pending 13-Nov-2019 A61K35/44
To view Karis Bio’s complete patent history, request access »

Karis Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karis Bio Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Korea Venture Investment Fund of Funds Minority
Yonsei Biohealth Technology Holdings Holding Company Minority
Yonsei University Technology Holdings University Minority
AJU IB Investment Venture Capital Minority
Devsisters Ventures Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Karis Bio FAQs

  • When was Karis Bio founded?

    Karis Bio was founded in 2020.

  • Where is Karis Bio headquartered?

    Karis Bio is headquartered in Seoul, South Korea.

  • What is the size of Karis Bio?

    Karis Bio has 36 total employees.

  • What industry is Karis Bio in?

    Karis Bio’s primary industry is Drug Discovery.

  • Is Karis Bio a private or public company?

    Karis Bio is a Private company.

  • What is Karis Bio’s current revenue?

    The current revenue for Karis Bio is .

  • How much funding has Karis Bio raised over time?

    Karis Bio has raised $95.3M.

  • Who are Karis Bio’s investors?

    Korea Venture Investment, Yonsei Biohealth Technology Holdings, Yonsei University Technology Holdings, AJU IB Investment, and Devsisters Ventures are 5 of 8 investors who have invested in Karis Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process